—
C+
C+ The full Closelook — membership. Open the C+ overview

Halozyme Therapeutics Inc (HALO) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Halozyme Therapeutics Inc

HALO in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Halozyme develops and licenses an enzyme called rHuPH20, which lets injectable biologic drugs be given under the skin instead of by intravenous infusion. It sells this enzyme technology to large drug makers, who build it into subcutaneous versions of their antibody treatments, and it also sells a small number of its own products directly. Revenue comes mainly from royalties and milestone payments tied to partner drugs such as those licensed to Roche, Pfizer and other pharmaceutical companies. It is based in San Diego.
Where it sits in the stack
Halozyme sits in our Healthcare sleeve, in the biotechnology sector, outside the AI build-out universe our index tracks. It behaves as a licensing business: partner pharmaceutical companies are the customers of its enzyme platform, and its own revenue is a function of how many of their subcutaneous drugs reach and stay on the market.
Who it is priced against
The diary does not carry a peer group for Halozyme; it can be read alongside other drug-delivery and formulation licensors that pharmaceutical companies use to convert intravenous drugs into subcutaneous ones.
Why Closelook tracks it
Halozyme holds no seat in our index and the diary has not quoted it. It carries a Closelook score, but with only one module scored so far, so the score is still being built.
What the diary watches
Whether existing licensing and royalty agreements with its pharmaceutical partners are renewed or extended, since its revenue depends on those partner drugs remaining in use.

Halozyme Therapeutics Inc (HALO) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for HALO, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Halozyme Therapeutics Inc (HALO)?

Halozyme Therapeutics Inc trades as HALO on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-18.

Is HALO in a Closelook index?

Not currently — Halozyme Therapeutics Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does HALO trade against its moving averages?

Uptrend stack intact: Trades +15.1% vs the 50-day and +44.9% vs the 200-day average, 1.3% below the 52-week high and +79.1% off the 52-week low; a golden cross printed 53 sessions ago. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Halozyme Therapeutics Inc do?

Halozyme develops and licenses an enzyme called rHuPH20, which lets injectable biologic drugs be given under the skin instead of by intravenous infusion. It sells this enzyme technology to large drug makers, who build it into subcutaneous versions of their antibody treatments, and it also sells a small number of its own products directly. Revenue comes mainly from royalties and milestone payments tied to partner drugs such as those licensed to Roche, Pfizer and other pharmaceutical companies. The diary does not carry a peer group for Halozyme; it can be read alongside other drug-delivery and formulation licensors that pharmaceutical companies use to convert intravenous drugs into subcutaneous ones.

Where does Halozyme Therapeutics Inc sit in the AI build-out?

Halozyme sits in our Healthcare sleeve, in the biotechnology sector, outside the AI build-out universe our index tracks. It behaves as a licensing business: partner pharmaceutical companies are the customers of its enzyme platform, and its own revenue is a function of how many of their subcutaneous drugs reach and stay on the market. Halozyme holds no seat in our index and the diary has not quoted it. It carries a Closelook score, but with only one module scored so far, so the score is still being built.

What does this page show?

A live price chart with SMA overlays and drawing tools for HALO, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe